Bionow | News

Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in th...

Apr 6th 2022

Catalent announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction ...

Catalent Biologics Completes $30 Million Project for Biopharmaceutical Developme...

Apr 6th 2022

Catalent announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutica...

Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Base...

Aug 4th 2021

Catalent announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, an...

Catalent Launches New OptiDose® Design Solution to Help Create Differentiated T...

Jul 27th 2021

Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market. Designed to incorporate recommendations from our ...

Catalent Receives RoSPA Gold Award for Health and Safety Practices

Jun 30th 2021

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents (RoSPA) for demonstrating high health and safety standards.

Catalent to Invest $10 Million to Expand High Potency Containment Capabilities f...

Dec 7th 2020

The investment will allow flexible jet milling operations to be carried out at Catalent’s sites in Malvern, Pennsylvania and Dartford, U.K., under containment to a working occupational exp...

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FD...

Nov 23rd 2020

Catalent has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therap...

Catalent Supports Rapid Development and Supply of Nocion Therapeutics’ Clinica...

Sep 28th 2020

Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been ...

T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Au...

Sep 23rd 2020

T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provide...

Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its ...

Sep 7th 2020

Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.

News